Grifols’ test kit to detect alpha-1-antitrypsin deficiency (alpha-1), called AlphaID At Home, is now available for consumers in the U.S., the company announced. The U.S. Food and Drug Administration (FDA) cleared the kit, which doesn’t require a medical prescription, last year, letting adults living in the U.S. assess…
La Mesa Rehab in San Diego — the sole comprehensive outpatient rehabilitation facility in the Southern California city — takes a holistic, innovative approach to pulmonary rehabilitation, which it emphasizes over pharmacological treatments for chronic obstructive pulmonary disease (COPD). Its COPD management strategy, of nonpharmacological therapy for pulmonary rehab,…
Primary healthcare provider VillageMD is partnering with the COPD Foundation to identify the “missing millions” thought to have chronic obstructive pulmonary disease (COPD) who remain undiagnosed and to improve access to pulmonary rehabilitation. The collaboration seeks to better identify and treat COPD at Village Medical clinics. A…
A first person with chronic obstructive pulmonary disease (COPD) has been dosed with ensifentrine, an inhaled medication in the pipeline of Verona Pharma, as part of a Phase 3 clinical trial that recently opened in China. The trial, called ENHANCE China (NCT05743075), is evaluating the efficacy…
A new remote monitoring program will offer personalized treatment to high-risk UC Davis Health patients with asthma and chronic obstructive pulmonary disease (COPD). The program is a collaboration between California-based UC Davis Health’s Operations Center of Excellence and precision digital health company Propeller Health. It will initially…
The national independent specialty pharmacy DirectRx has joined the COPD Foundation’s Corporate Social Responsibility program to help support patients with chronic obstructive pulmonary disease (COPD) and find better treatments, . DirectRx’s membership brings to 23 the companies that fall under the foundation’s corporate sponsorship program. The program…
Dupixent (dupilumab) — a medication initially approved for exzema — was found to significantly reduce the number of disease exacerbations and to improve lung function in people with chronic obstructive pulmonary disease (COPD), meeting the primary and key secondary goals of the pivotal Phase 3 BOREAS trial. A similarly…
Remote monitoring reduced hospitalization rates and emergency room visits for patients with chronic obstructive pulmonary disease (COPD), a recent study has shown. At the same time, outpatient office visits increased, suggesting remote patient monitoring may help shift care to a less expensive and burdensome setting. “These results support the…
Therapeutic Solutions International (TSOI) reported discovering a new mechanism of action for JadiCell, its investigative stem cell therapy for chronic obstructive pulmonary disease (COPD) and other conditions. Working in animal models, scientists found that JadiCell’s protective effects were dependent on certain immune B-cells and a signaling molecule…
The National Heart, Lung, and Blood Institute (NHLBI) has awarded $13 million for research focused on the link between the lung endothelium — a thin layer of cells, called endothelial cells, lining the inside of blood vessels in the lungs — and inflammation in lung diseases, including chronic obstructive…
Get regular updates to your inbox.